Not a candidate for refractive surgery? Not anymore!
August 1st 2013Ophthalmology Times introduces this new series called “Gloves Off with Gulani” that is part of the full-spectrum concept of a “super-specialty,” in which Arun C. Gulani, MD, will present prototype case studies and accept input to show how every case-no matter how difficult-deserves a mindset of emmetropia. Look for the first “gloves-off” encounter-“Multifocal IOL nightmare: Reversed to 20/20”-in the Oct. 1 issue of Ophthalmology Times.
French commission favors reimbursement of Iluvien
July 29th 2013The Transparency Commission of the French National Authority for Health has issued a favorable opinion for the reimbursement and hospital listing of Alimera Sciences’ fluocinolone acetonide intravitreal implant (Iluvien) for the treatment of chronic diabetic macular edema.
Digital devices help physicians stay connected to research
July 29th 2013Ophthalmologists and other physicians are finding it more challenging to stay on top of all the clinical research and information that is presented before them. However, digital devices may provide an answer to help physicians absorb all this information.
DES market expected to grow about $4 billion in 10 years
July 25th 2013As dry eye syndrome (DES) affects more and more patients over the next 10 years, pharmaceutical companies are expecting to expand their clinical products globally to treat the condition, thus tripling the market’s global revenue over the next decade.
How use of a shunt device may augment deep sclerectomy
July 22nd 2013Deep sclerectomy augmented with implantation of a gold mini-shunt (Gold Mini Shunt Plus, SOLX) in the suprachoroidal space is a safe and effective technique for lowering IOP in eyes with moderate to advanced open-angle glaucoma, according to findings from researchers at the University of Montreal.
B + L buys option to license new dry eye compound
July 22nd 2013Bausch + Lomb (B + L) has acquired an option to license an investigational compound currently in phase II development for the treatment of dry eye syndrome. The compound, called MIM-D3 and developed by Mimetogen Pharmaceuticals Inc., has the potential to be the first in a new class of agents called TrkA agonists, said the companies in a joint statement.
Meaningful pharmacologic pupil dilation possible after death
July 15th 2013Pupils can be pharmacologically dilated after death, according to the results of a recent study. The study examined pupillary dilation of postmortem eye bank eyes, which may facilitate postmortem examination and screening through modalities such as fundus photography and fundus optical coherence tomography.
Slow-release therapy for AMD, DME on horizon
July 15th 2013Slow release of surrogate proteins over several months has been demonstrated in vitro from injectable hydrogel depots. This technology could help create long-term, sustained-release treatments of anti-vascular endothelial growth factor drugs.
Report: Eye disorders cost $139 billion per year
July 15th 2013Through improved communication and coordination with patients and other health care professionals as well as advocacy for increased or maintained funding for prevention of vision-related problems, ophthalmologists can help decrease costs associated with eye disorders and vision loss, according to a report commissioned by Prevent Blindness America.